IBRXImmunityBio Inc.
Chart data are delayed by 15 minutes.
Main metrics
Providers
All 2 issuers →
RobinhoodIBRX$38.43K100.0%
Anchored FinanceaIBRX—0.0%Chains
All 5 chains →
Robinhood Chain$38.43K100.0%
Arbitrum One—0.0%
Base—0.0%
Ethereum—0.0%
Monad—0.0%About IBRX
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.
Valuation
Profitability
Balance sheet
Trading
| Issuer | Token | Chains | Dividend | Shares | Value | Share |
|---|---|---|---|---|---|---|
| Robinhood | IBRXImmunityBio, (Robinhood) | | 4.8K | $38.43K | 100.0% | |
| Anchored Finance | aIBRXImmunitybio Inc aStock | | 0 | — | 0.0% |
| Chain | Issuers | Shares | Value | Share |
|---|---|---|---|---|
| Robinhood Chain | | 4.8K | $38.43K | 100.0% |
| Arbitrum One | | 0 | — | 0.0% |
| Base | | 0 | — | 0.0% |
| Ethereum | | 0 | — | 0.0% |
| Monad | | 0 | — | 0.0% |
No dividend has been recorded for this asset.
No corporate event has been recorded for this asset.
